CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
05 Jun 2019
Historique:
received: 16 04 2019
revised: 24 05 2019
accepted: 27 05 2019
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 4 12 2019
Statut: epublish

Résumé

The advent of CD19-specific chimeric antigen receptor (CAR) T cells has proven to be a powerful asset in the arsenal of cancer immunotherapy of acute lymphoblastic leukemia and certain B cell lymphomas. However, a sizable portion of patients treated with CD19-CAR T cells relapse with CD19-negative cancer cells, necessitating the quest for back-up antigens. Chondroitin sulfate proteoglycan 4 (CSPG4) expression has been reported on leukemic blasts bearing the ill-fated

Identifiants

pubmed: 31195686
pii: ijms20112764
doi: 10.3390/ijms20112764
pmc: PMC6600602
pii:
doi:

Substances chimiques

Antigens 0
Antigens, Neoplasm 0
Cytokines 0
Proteoglycans 0
chondroitin sulfate proteoglycan 4 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : SCHA 1247/3-1

Références

Cancer Immunol Immunother. 2000 Mar;48(12):691-702
pubmed: 10752477
Leukemia. 2000 Jul;14(7):1232-8
pubmed: 10914547
J Immunol. 2001 Dec 1;167(11):6123-31
pubmed: 11714771
Leukemia. 2003 Aug;17(8):1589-95
pubmed: 12886247
Leukemia. 2004 Feb;18(2):227-32
pubmed: 14671638
Mod Pathol. 1992 Jul;5(4):415-9
pubmed: 1495947
Crit Rev Immunol. 2004;24(4):267-96
pubmed: 15588226
Ann N Y Acad Sci. 2004 Dec;1028:340-50
pubmed: 15650259
Prostate. 2006 Feb 15;66(3):294-304
pubmed: 16245280
Cancer Immunol Immunother. 2006 Sep;55(9):1132-41
pubmed: 16344988
Oncogene. 2006 May 11;25(20):2873-84
pubmed: 16407841
Ophthalmic Res. 2006;38(5):251-4
pubmed: 16888406
Melanoma Res. 2008 Apr;18(2):73-84
pubmed: 18337643
Cancer Immunol Immunother. 2009 Mar;58(3):415-27
pubmed: 18677475
J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512
pubmed: 20852124
Mol Cancer. 2010 Nov 23;9:301
pubmed: 21092273
J Clin Oncol. 2011 Jan 10;29(2):214-22
pubmed: 21135279
Mol Ther. 2011 Apr;19(4):760-7
pubmed: 21326215
Cancer Res. 2011 Dec 15;71(24):7410-22
pubmed: 22021902
Clin Cancer Res. 2012 Oct 1;18(19):5352-63
pubmed: 22893632
Blood. 2013 Feb 14;121(7):1165-74
pubmed: 23243285
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
Clin Cancer Res. 2014 Feb 15;20(4):962-71
pubmed: 24334762
J Immunol. 2014 Jun 15;192(12):5451-8
pubmed: 24907378
Cancer Immunol Immunother. 2014 Oct;63(10):999-1008
pubmed: 24938475
Cancer Lett. 2014 Oct 1;352(2):228-35
pubmed: 25016058
J Immunother Cancer. 2014 Aug 19;2:25
pubmed: 25197555
Theranostics. 2015 Feb 15;5(5):530-44
pubmed: 25767619
Cancer Biol Ther. 2015;16(9):1323-31
pubmed: 26178065
J Clin Invest. 2015 Sep;125(9):3392-400
pubmed: 26325036
Cancer Immunol Immunother. 2015 Dec;64(12):1623-35
pubmed: 26515978
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Transl Oncol. 2016 Feb;9(1):57-63
pubmed: 26947882
Int J Cancer. 2016 Aug 15;139(4):916-27
pubmed: 27037627
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Cell Discov. 2016 May 17;2:16008
pubmed: 27462455
Nat Immunol. 2016 Nov;17(11):1322-1333
pubmed: 27595233
Front Pediatr. 2017 Feb 09;5:4
pubmed: 28232907
Nature. 2017 May 24;545(7655):423-431
pubmed: 28541315
Biomedicines. 2017 Jun 28;5(3):
pubmed: 28657611
Cancer Immunol Immunother. 2017 Nov;66(11):1473-1484
pubmed: 28721449
BMC Cancer. 2017 Aug 17;17(1):551
pubmed: 28818060
Transl Cancer Res. 2016 Aug;5(Suppl 2):S221-S225
pubmed: 28824851
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Front Immunol. 2018 Jan 10;8:1911
pubmed: 29375561
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Sci Transl Med. 2018 Feb 28;10(430):
pubmed: 29491184
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Mol Ther. 2018 Sep 5;26(9):2218-2230
pubmed: 30055872
Mol Cell Biol. 2018 Oct 15;38(21):
pubmed: 30104252
Cancer Discov. 2018 Oct;8(10):1219-1226
pubmed: 30135176
Nat Med. 2018 Oct;24(10):1504-1506
pubmed: 30275569
Nat Med. 2018 Oct;24(10):1492-1493
pubmed: 30297897
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
J Natl Cancer Inst. 1983 Aug;71(2):259-63
pubmed: 6576184
Blood. 1996 Feb 1;87(3):1123-33
pubmed: 8562938
Blood. 1996 Feb 1;87(3):1134-9
pubmed: 8562939
Blood. 1997 May 15;89(10):3801-5
pubmed: 9160687

Auteurs

Dennis C Harrer (DC)

Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany. dennis.harrer@uk-erlangen.de.

Gerold Schuler (G)

Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany. gerold.schuler@uk-erlangen.de.

Jan Dörrie (J)

Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany. jan.doerrie@uk-erlangen.de.

Niels Schaft (N)

Department of Dermatology, Universtitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Hartmannstraße 14, 91052 Erlangen, Germany. niels.schaft@uk-erlangen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH